Which monoclonal antibody clone should be used for MTAP immunohistochemistry in variant carcinoma work‑up in India, and where can it be obtained?

MTAP Immunohistochemistry for Variant Carcinoma Work-up in India

For MTAP immunohistochemistry in variant carcinoma work-up, use monoclonal antibody clone 1813 (NBP2-75730, Novus Biologicals), which demonstrates superior performance with stronger immunoreactivity, more specific staining, and no equivocal interpretations compared to the commonly used EPR6893 clone 1.

Antibody Clone Selection

The evidence strongly favors clone 1813 over EPR6893 based on a direct comparison study in mesothelioma specimens 1:

• Clone 1813 advantages:

  • Stronger cytoplasmic immunoreactivity
  • More specific staining patterns
  • Zero equivocal interpretations
  • 96% sensitivity and 86% specificity for detecting 9p21 homozygous deletion
  • 93% overall accuracy
  • Near-perfect agreement with molecular testing (κ = 0.85)

• Clone EPR6893 limitations:

  • Equivocal staining in 34% of cases
  • Weak or heterogeneous immunoreactivity
  • Lack of definitive internal positive controls
  • Nonspecific background staining

Clinical Context and Interpretation

MTAP immunohistochemistry serves as a surrogate marker for CDKN2A/9p21 homozygous deletion, which is critical for distinguishing malignant mesothelioma from benign mesothelial proliferations 2, 3, 2. Loss of MTAP cytoplasmic staining shows 96% specificity and 86% sensitivity for detecting homozygous CDKN2A deletion 2.

Important Caveats:

1. Tumor-type specificity matters: While MTAP IHC performs excellently in pleural mesothelioma, recent evidence shows it is not reliable in peritoneal mesothelioma, where concordance with CDKN2A deletion is poor (Kappa = 0.091) 4. This highlights tissue-specific validation requirements.

2. MTAP IHC is superior to NGS panels for MTAP assessment: In NSCLC, CDKN2A loss by next-generation sequencing overestimates MTAP loss in more than 25% of cases, as CDKN2A deletion does not always correlate with MTAP loss 5. MTAP IHC directly assesses protein expression and is more accurate than using CDKN2A as a surrogate.

3. Interpretation requires proper controls: Normal mesothelial cells, stromal cells, or lymphocytes should serve as internal positive controls. Complete loss of cytoplasmic staining in tumor cells with retained staining in controls indicates MTAP deficiency 3, 1.

Procurement in India

Novus Biologicals antibody clone 1813 (catalog NBP2-75730) can be obtained through:

• International distributors with Indian operations
• Direct ordering from Novus Biologicals (Bio-Techne brand)
• Local scientific supply companies that distribute Bio-Techne products

The antibody should be validated in your laboratory before clinical use, following standard immunohistochemistry validation protocols for formalin-fixed, paraffin-embedded tissue.

Practical Application Algorithm

1. Use MTAP IHC with clone 1813 on formalin-fixed, paraffin-embedded tissue sections
2. Evaluate cytoplasmic staining in tumor cells versus internal controls
3. Interpret as:
   • Loss: Complete absence of cytoplasmic staining in tumor cells with retained staining in controls
   • Retained: Any cytoplasmic positivity in tumor cells
4. For pleural mesothelioma specifically: Loss of MTAP supports malignancy diagnosis and can be used alongside BAP1 IHC or CDKN2A FISH 3, 2
5. For other tumor types: Validate performance in your specific context, as tissue-specific differences exist 4

Additional Considerations

MTAP deficiency has emerging therapeutic implications beyond diagnosis. MTAP-deleted tumors are vulnerable to PRMT5 and MAT2A inhibitors through synthetic lethality 6. This makes accurate MTAP assessment increasingly important for both diagnostic and therapeutic decision-making, particularly in NSCLC where MTAP deletions occur in approximately 10% of cases 5, 7.